These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 8355435)

  • 21. [A study of the relation between clinical prognostic factors and the estimated tumor growth speed in superficial bladder cancer].
    Ota T; Akaza H
    Nihon Hinyokika Gakkai Zasshi; 1996 May; 87(5):851-6. PubMed ID: 8691710
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Bacillus Calmette-Guerin versus doxorubicin versus thiotepa: a randomized prospective study in 202 patients with superficial bladder cancer.
    Martínez-Piñeiro JA; Jiménez León J; Martínez-Piñeiro L; Fiter L; Mosteiro JA; Navarro J; García Matres MJ; Cárcamo P
    J Urol; 1990 Mar; 143(3):502-6. PubMed ID: 2106041
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Microstaging of pT1 transitional cell carcinoma of the bladder. Does it really differentiate two populations with different prognoses? (pT1 subcategory).
    Sözen S; Akbal C; Sökmensüer C; Ekici S; Ozen H
    Urol Int; 2002; 69(3):200-6. PubMed ID: 12372888
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Positive urinary cytology following a complete response to intravesical bacillus Calmette-Guerin therapy: pattern of recurrence.
    Schwalb MD; Herr HW; Sogani PC; Russo P; Sheinfeld J; Fair WR
    J Urol; 1994 Aug; 152(2 Pt 1):382-7. PubMed ID: 8015076
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Can re-cTURBT be useful in pT1HG disease as a risk indicator of recurrence and progression? A single centre experience.
    Giulianelli R; Gentile BC; Mirabile G; Albanesi L; Tariciotti P; Rizzo G; Buscarini M; Vermiglio M
    Arch Ital Urol Androl; 2017 Dec; 89(4):272-276. PubMed ID: 29473376
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Combined local bladder hyperthermia and intravesical chemotherapy for the treatment of high-grade superficial bladder cancer.
    Gofrit ON; Shapiro A; Pode D; Sidi A; Nativ O; Leib Z; Witjes JA; van der Heijden AG; Naspro R; Colombo R
    Urology; 2004 Mar; 63(3):466-71. PubMed ID: 15028439
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Squamous differentiation in patients with superficial bladder urothelial carcinoma is associated with high risk of recurrence and poor survival.
    Li G; Yu J; Song H; Zhu S; Sun L; Shang Z; Niu Y
    BMC Cancer; 2017 Aug; 17(1):530. PubMed ID: 28789622
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Local microwave hyperthermia and intravesical chemotherapy as bladder sparing treatment for select multifocal and unresectable superficial bladder tumors.
    Colombo R; Da Pozzo LF; Lev A; Salonia A; Rigatti P; Leib Z; Servadio C; Caldarera E; Pavone-Macaluso M
    J Urol; 1998 Mar; 159(3):783-7. PubMed ID: 9474148
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Bacillus Calmette-Guerin therapy after the second transurethral resection significantly decreases recurrence in patients with new onset high-grade T1 bladder cancer.
    Iida K; Naiki T; Kawai N; Etani T; Ando R; Ikegami Y; Okamura T; Kubota H; Okada A; Kohri K; Yasui T
    BMC Urol; 2016 Feb; 16():8. PubMed ID: 26920373
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Oncological outcomes of a single but extensive transurethral resection followed by appropriate intra-vesical instillation therapy for newly diagnosed non-muscle-invasive bladder cancer.
    Koie T; Ohyama C; Hosogoe S; Yamamoto H; Imai A; Hatakeyama S; Yoneyama T; Hashimoto Y; Yoneyama T; Tobisawa Y; Mori K
    Int Urol Nephrol; 2015 Sep; 47(9):1509-14. PubMed ID: 26149637
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prospective evaluation of Ki-67 labeling in predicting the recurrence and progression of superficial bladder transitional cell carcinoma.
    Blanchet P; Droupy S; Eschwege P; Viellefond A; Paradis V; Pichon MF; Jardin A; Benoit G
    Eur Urol; 2001 Aug; 40(2):169-75. PubMed ID: 11528194
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Preselected biopsy for normal-appearing mucosa of superficial bladder carcinoma.
    Miyao N; Hisataki T; Takahashi A; Masumori N; Satoh M; Tsukamoto T
    Eur Urol; 1998; 34(5):404-10. PubMed ID: 9803003
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinical panurothelial disease in patients with superficial bladder tumors: therapeutic implications.
    Solsona E; Iborra I; Ricos JV; Monros JL; Rubio J; Almenar S
    J Urol; 2002 May; 167(5):2007-11. PubMed ID: 11956428
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Conservative treatment of high-risk (T1G3) transitional carcinoma].
    Catanzaro F; Torelli F; Catanzaro M; Cappellano F; Pizzoccaro M; Baruffi M; Sironi D; Pozzoli GL
    Arch Ital Urol Androl; 1996 Feb; 68(1):21-4. PubMed ID: 8664915
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Results of radical cystectomy for management of invasive bladder cancer with special reference to prognostic factors and quality of life depending on the type of urinary diversion].
    Słojewski M
    Ann Acad Med Stetin; 2000; 46():217-29. PubMed ID: 11712306
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Role of BCG in T1G3 bladder transitional cell carcinoma (TCC): our experience].
    Comeri GC; Belvisi P; Conti G; Cretarola E; Duvia R; Furgoni R; Gianneo E; Radice GP
    Arch Ital Urol Androl; 1996 Feb; 68(1):55-9. PubMed ID: 8664924
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Statistical evaluation of determinants of progression of superficial bladder cancer by proportional hazards model].
    Takashi M; Sakata T; Murase T; Takagi Y; Nagai T; Sahashi M; Shimoji T; Miyake K; Hamajima N
    Nihon Hinyokika Gakkai Zasshi; 1990 Jan; 81(1):116-21. PubMed ID: 2304308
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clinical outcome of tumor recurrence for Ta, T1 non-muscle invasive bladder cancer from the data on registered bladder cancer patients in Japan: 1999-2001 report from the Japanese Urological Association.
    Kikuchi E; Fujimoto H; Mizutani Y; Okajima E; Koga H; Hinotsu S; Shinohara N; Oya M; Miki T;
    Int J Urol; 2009 Mar; 16(3):279-86. PubMed ID: 19207609
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Combined modality treatment with bladder preservation for muscle invasive bladder cancer.
    Sabaa MA; El-Gamal OM; Abo-Elenen M; Khanam A
    Urol Oncol; 2010; 28(1):14-20. PubMed ID: 18818110
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Management of high-risk non-muscle invasive bladder cancer.
    Brausi M; Olaru V
    Minerva Urol Nefrol; 2012 Dec; 64(4):255-60. PubMed ID: 23288212
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.